₹574.15
+1.76%NSE close, 16 Nov 2026
+16.94%
Metropolis Healthcare is a small cap company in the Healthcare sector, listed on NSE under the symbol METROPOLIS. At ₹574.15 a share, the market values the whole company at ₹11,907 crore.
In FY26, it reported sales of ₹1,646 crore and a net profit of ₹190 crore, an operating margin of 24.4%. Over the last three years, sales grew 12.8% a year and net profit grew 10.0% a year.
The market values the company at 53.1 times its profit over the last twelve months and 7.25 times its book value; its return on equity is 13.7% and it has almost no borrowings.
Promoters hold 47.82% of the shares, and have pledged 1.2% of their holding. Foreign institutions hold 11.67%, and domestic institutions, mutual funds among them, 35.49%.
Over the past year the share price has risen 14.5%, and it is 5.7% below its 52-week high.
Companies of a similar size in the same sector include Marksans Pharma, Rainbow Childrens Medicare, Concord Biotech and Akums Drugs and Pharmaceuticals.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Metropolis Healthcare | ₹574.15 | ₹11,907 cr | 53.1 | 13.7% | +15.80% | +14.50% |
| Marksans Pharma | ₹309.20 | ₹14,016 cr | 25.0 | 16.8% | +30.50% | +67.52% |
| Rainbow Childrens Medicare | ₹1,276.80 | ₹12,968 cr | 44.4 | 17.0% | +23.20% | −6.37% |
| Concord Biotech | ₹581.00 | ₹12,156 cr | 43.0 | 13.6% | +25.10% | −17.67% |
| Akums Drugs and Pharmaceuticals | ₹722.20 | ₹11,367 cr | 31.2 |
Transcript
Meeting with investors scheduled on November 16, 2026
Link of Recording
Metropolis Healthcare reports strong Q2 FY27 performance, with revenue up 16% to Rs. 497 crore and PAT up 43% to Rs. 75 crore
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 | 497 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 | 311 | 317 | 339 | 363 |
| Operating profit | 64.9 | 80.0 | 78.8 | 89.9 | 72.0 | 62.3 | 89.8 | 108 | 94.9 | 108 | 111 | 134 |
| Operating margin | 22.3% | 24.2% | 25.1% | 25.7% | 22.3% | 18.0% | 23.3% | 25.2% | 23.4% | 25.4% | 24.7% | 27.0% |
| Other income | 2.3 | 2.5 | 2.5 | 3.1 | 2.6 | 7.0 | 7.5 | 0.9 | 9.0 | 8.2 | 5.1 | 8.5 |
| Interest | 5.3 | 5.6 | 4.7 | 4.8 | 4.5 | 4.6 | 5.2 | 5.7 | 5.7 | 7.9 | 6.2 | 7.0 |
| Depreciation | 25.0 | 26.4 | 25.5 | 26.8 | 27.7 | 28.6 | 30.9 | 32.4 | 31.9 | 38.6 | 32.4 | 33.1 |
| Profit before tax | 36.9 | 50.5 | 51.1 | 61.4 | 42.3 | 36.0 | 61.2 | 71.0 | 57.2 | 69.8 | 77.7 | 102 |
| Tax | 9.6 | 14.0 | 13.0 | 14.7 | 10.9 | 6.8 | 16.0 | 18.1 | 15.1 | 18.8 | 20.8 | 27.0 |
| Net profit | 27.2 | 36.4 | 38.0 | 46.5 | 31.4 | 29.1 | 45.1 | 52.7 | 41.4 | 50.9 | 56.7 | 75.3 |
| EPS (₹) | 5.30 | 7.11 | 7.41 | 9.08 | 6.11 | 5.69 | 8.70 | 10.17 | 7.99 | 2.46 | 2.73 | 3.64 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | 1,646 |
| Expenses | 561 | 624 | 712 | 886 | 860 | 925 | 1,028 | 1,245 |
| Operating profit | 200 | 233 | 286 | 343 | 288 | 283 | 303 | 401 |
| Operating margin | 26.3% | 27.2% | 28.7% | 27.9% | 25.1% | 23.4% | 22.8% | 24.4% |
| Other income | 8.2 | 8.6 | 12.1 | 17.6 | 15.2 | 9.1 | 15.1 | 25.6 |
| Interest | 0.5 | 8.3 | 7.8 | 19.7 | 26.8 | 22.5 | 18.6 | 24.5 |
| Depreciation | 20.1 | 39.3 | 45.9 | 63.2 | 89.2 | 94.5 | 109 | 134 |
| Profit before tax | 187 | 169 | 244 | 293 | 188 | 175 | 191 | 259 |
| Tax | 62.9 | 41.2 | 61.0 | 78.7 | 44.1 | 46.2 | 45.3 | 68.0 |
| Net profit | 120 | 127 | 183 | 214 | 143 | 128 | 145 | 190 |
| EPS (₹) | 24.06 | 25.36 | 35.97 | 41.87 | 27.91 | 24.95 | 28.29 | 9.19 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 988 | 1,096 | 1,331 | 1,513 | 1,642 |
| Borrowings | 79.1 | 0 | 14.2 | 18.7 | 17.0 |
| Total liabilities | 511 | 456 | 533 | 614 | 687 |
| Fixed assets | 137 | 156 | 190 | 215 | 222 |
| Investments | 1.8 | 1.8 | 1.8 | 1.8 | 0 |
| Cash and equivalents | 68.8 | 62.6 | 39.5 | 54.8 | 68.7 |
| Total assets | 1,502 | 1,555 | 1,867 | 2,138 | 2,341 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 253 | 263 | 351 | 223 |
| From investing | −735 | −201 | −223 | −145 |
| From financing | 163 | −86.6 | −115 | −70.7 |
| Spent on fixed assets | −30.7 | −43.4 | −43.5 | −15.5 |
| Free cash flow | 223 | 219 | 307 | 207 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 15.8% | 14.9% | 18.3% | 17.4% | 12.4% | 10.6% | 10.9% | 11.5% |
| Operating margin | 26.3% | 27.2% | 28.7% | 27.9% | 25.1% | 23.4% | 22.8% | 24.4% |
| Return on equity | – | – | – | – | 14.5% | 11.7% | 10.9% | 12.6% |
| Return on capital employed | – | – | – | – | 20.1% | 18.0% | 15.6% | 18.5% |
| Return on assets | – | – | – | – | 9.5% | 8.2% | 7.8% | 8.9% |
| Debt to equity | – | – | – | – | 0.08 | 0.00 | 0.01 | 0.01 |
| Interest coverage | 353.00 | 21.30 | 32.40 | 15.90 | 8.00 | 8.70 | 11.30 | 11.60 |
| Debt to assets | – | – | – | – | 0.05 | 0.00 | 0.01 | 0.01 |
| Current ratio | – | – | – | – | 1.14 | 1.28 | 1.18 | 1.40 |
| Quick ratio | – | – | – | – | 0.97 | 1.13 | 1.01 | 1.27 |
| Cash ratio | – | – | – | – | 0.26 | 0.25 | 0.13 | 0.16 |
| Asset turnover | – | – | – | – | 0.76 | 0.78 | 0.71 | 0.77 |
| Fixed asset turnover | – | – | – | – | 8.37 | 7.75 | 7.00 | 7.64 |
| Inventory turnover | – | – | – | – | – | 6.30 | 5.60 | 7.10 |
| Receivables turnover | – | – | – | – | 9.40 | 9.60 | 9.00 | 9.70 |
| Gross margin | – | – | – | – | – | 79.9% | 79.8% | 80.3% |
| Cash from operations to profit | – | – | – | 118.0% | – | – | 181.0% | 185.0% |
| Effective tax rate | 33.7% | 24.3% | 25.0% | 26.8% | 23.5% | 26.5% | 23.8% | 26.2% |
| 10.4% |
| +31.90% |
| +56.88% |
| Park Medi World | ₹245.03 | ₹10,584 cr | 41.3 | 11.9% | n/a | n/a |
|---|
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
|---|
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
|---|
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
|---|
The declaration of Interim Dividend and record date.
Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Re. 1 per equity share.
The financial results for the period ended September 30, 2026.
Allotment of 65,600 Equity Shares under the Metropolis-Restrictive Stock Unit Plan, 2020
Grant of Stock Benefits
Schedule of Q2FY27 earnings conference call (i.e. post earnings/quarterly call), organized by BNP Paribas Securities India on Wednesday, November 04, 2026 at 09:00 a.m. (IST) to discuss the financial results of the Company for the quarter and half year ended September 30, 2026
Allotment of 9,516 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020.
Business update for Q2FY27
Allotment of 66,312 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020.